Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. [electronic resource]
Producer: 20191206Description: e184475 p. digitalISSN:- 2374-2445
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- chemistry
- Class I Phosphatidylinositol 3-Kinases -- antagonists & inhibitors
- Disease Progression
- Estrogen Receptor Antagonists -- administration & dosage
- Female
- Fulvestrant -- administration & dosage
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Mutation
- Progression-Free Survival
- Protein Kinase Inhibitors -- administration & dosage
- Receptors, Estrogen -- analysis
- Thiazoles -- administration & dosage
- Time Factors
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.